AI-Driven Demand Boosts Twist Bioscience Sales, But Loss Widens

Twist Bioscience reported revenue of $110.72 million, ahead of both the $107.66 million consensus and management's $107 million-$108 million guide, though adjusted EPS was a 59-cent loss versus a 48-cent expected loss. Fiscal 2026 sales guidance was raised to $442 million-$447 million from $435 million-$440 million, and Q3 revenue guidance of $114 million-$115 million also topped consensus. The quarter benefited from 28% growth in DNA Synthesis and Protein Solutions and continued AI-enabled drug discovery strength, while the company also disclosed a $17.1 million securities class action settlement in principle.

Analysis

This print is more important for mix and commercialization velocity than for near-term earnings power. The growth engine is increasingly being pulled by AI-adjacent drug discovery workflows, which matters because those customers tend to scale assays and gene counts faster once workflows are embedded; that can create a multi-quarter revenue compounding effect even if headline profitability remains distant. The key second-order signal is that utilization is rising without obvious pricing pressure, suggesting the company may be leveraging a differentiated technical moat rather than simply buying growth.

The market is likely underappreciating the balance between revenue momentum and litigation overhang. The settlement clears a large psychological risk, but the booked cost will keep reported profitability noisy for several quarters, which can cap multiple expansion unless investors look through GAAP optics. More importantly, the guidance raise implies management has better visibility into demand than the sell-side, and that tends to matter more for a tools/platform name than a one-quarter EPS miss.

The main risk is that the AI-drug-discovery enthusiasm is being conflated with durable, broad-based end-market demand. If academic and government demand softens or the AI workflow mix normalizes, growth could decelerate quickly and expose how much of the current premium is tied to expectation rather than recurring volume. The other watchpoint is margin: if complex gene synthesis ramps before economics are fully optimized, gross margin expansion could stall and push the EBITDA breakeven timeline back by 1-2 quarters.

Contrarian view: the 4% selloff looks more like an earnings-quality and litigation-response de-risking event than a fundamental break. For investors who can tolerate volatility, the combination of raised revenue guide, expanding customer count, and a new product launch creates a better setup for a 3-6 month re-rating than the headline EPS miss implies. The better trade is to own the operating leverage story before the market fully prices the guidance raise and product expansion.

Key Decisions for Investors

• Go long TWST on a 2-6 week horizon on weakness into the post-earnings selloff; risk/reward favors upside if the market shifts focus from the EPS miss to raised FY26 revenue guidance and accelerating mix.
• Buy TWST Jan-2026 or Apr-2026 call spreads to express the view that guidance credibility plus new-product optionality can re-rate the stock over 2-3 quarters; capped downside versus common.
• Pair trade: long TWST / short a lower-growth life science tools peer with weaker AI-drug-discovery exposure over the next 1-2 quarters to isolate relative operating momentum and product-catalyst optionality.
• If TWST rallies back toward pre-earnings levels within days, consider trimming into strength: the litigation cleanup reduces tail risk, but margin progression still needs proof before a full multiple expansion is warranted.
• Set a catalyst watch on next-quarter gross margin and complex genes adoption metrics; if gross margin fails to hold above the mid-50s or guide stalls, exit long exposure quickly because the breakeven story becomes harder to underwrite.